Institutional Confidence in GTX-102 Fuels Optimism for Ultragenyx Pharmaceutical (RARE)

On May 21, Cantor Fitzgerald expert Kristen Kluska maintained an Overweight standing connected Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) and raised the terms people from $84 to $96. This valuation accommodation is based connected the increasing organization assurance successful the underlying concern lawsuit for GTX-102, which is utilized to dainty Angelman syndrome.

Tonhom1009/Shutterstock.com

Due to highly favorable investigating parameters, Kluska says that the objective plus present shows a importantly higher likelihood of eventual success. This optimistic appraisal is heavy driven by the circumstantial structural plan of its Phase 3 trial. Specifically, the broad valuation utilizes the Bayley-4 cognitive earthy people alongside the MDRI metric to measurement efficacy.

By organizing the objective architecture successful this manner, it tin successfully found 2 wholly autarkic pathways to execute ceremonial statistical success, thereby mitigating developmental hazard and strengthening the broader merchandise portfolio.

On May 8, the terms people connected Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) was reduced by Wedbush from $27 to $26, which inactive yields astir 14% upside astatine the existent level. The steadfast maintained a Neutral standing connected the stock. Although the gross underperformance is upsetting, absorption reaffirmed each aspects of the fiscal twelvemonth 2026 gross projection. The steadfast besides anticipates that Crysvita volition close its people during the remainder of the year.

Wedbush besides expects the institution to crook profitable sometime successful 2027. Predominantly, Ultragenyx has 2 PDUFAs for DTX401 and UX111, some of which connection a accidental for profitable PRVs, portion Wedbush is awaiting Phase 3 ASPIRE results for GTX102.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) develops caller therapies, with a absorption connected identifying, acquiring, and commercializing products for uncommon and ultra-rare familial diseases. It has a beardown accent connected cistron therapy and covers assorted stages of objective trials. The institution is presently going done precocious currency pain with the purpose of turning profitable from 2027 onwards.

While we admit the imaginable of RARE arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and 15 Stocks That Will Make You Rich successful 10 Years.

Disclosure: None. Follow Insider Monkey connected Google News.